Clinical trial
Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
NCT00113048 · Genzyme, a Sanofi Company, Industry · Terminated
Key facts
| NCT number | NCT00113048 |
|---|---|
| Title | Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies |
| Official title | A Phase I Study of Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hematologic Malignancies |
| Intervention type | Drug |
| Interventions | CAMPATH (alemtuzumab) |
| Enrollment | 24 |
| Start date | Dec 1, 2003 |
| Completion | Sep 1, 2005 |
| First posted | Jun 6, 2005 |
| Last update posted | Feb 5, 2014 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: